| Literature DB >> 30843736 |
Yassine Aimene1,2,3, Romain Eychenne2,3, Sonia Mallet-Ladeira4, Nathalie Saffon4, Jean-Yves Winum5, Alessio Nocentini6, Claudiu T Supuran6, Eric Benoist2,3, Achour Seridi1.
Abstract
In this work, two bidentate 2-pyridyl-1,2,3-triazole ligands (3a and 3b) containing aEntities:
Keywords: Click chemistry; DFT calculations; carbonic anhydrase inhibitors; crystal structures; rhenium(I) complexes
Mesh:
Substances:
Year: 2019 PMID: 30843736 PMCID: PMC6407592 DOI: 10.1080/14756366.2019.1585835
Source DB: PubMed Journal: J Enzyme Inhib Med Chem ISSN: 1475-6366 Impact factor: 5.051
Crystal data and structure refinement for 3a, 3b, 4a, and 4b.
| Pyta ligands | Rhenium complexes | |||
|---|---|---|---|---|
| Empirical formula | C13H11N5O2S | C14H13N5O2S | C16H11ClN5O5ReS | C17H13ClN5O5ReS, CH4O |
| Formula weight | 301.33 | 315.35 | 607.01 | 653.08 |
| T [K] | 193(2) | 193(2) | 193(2) | 193(2) |
| Wavelength [Å] | 1.54178 | 0.71073 | 0.71073 | 0.71073 |
| Crystal system | Triclinic | Monoclinic | Orthorhombic | Triclinic |
| Space group | ||||
| Unit cell dimensions [Å, °] | a = 6.3545(2) | a = 15.8111(9) | a = 19.1728(15) | a = 7.7195(5) |
| b = 7.0441(2) | b = 10.6289(5) | b = 15.1735(11) | b = 12.1870(7) | |
| c = 29.2801(7) | c = 8.4974(4) | c = 13.1204(11) | c = 13.1222(8) | |
| α = 95.856(2) | α = 90 | α = 90 | α = 108.398(2) | |
| β = 90.497(2) | β = 104.485(2) | β = 90 | β = 98.897(2) | |
| γ = 96.930(2) | γ = 90 | γ = 90 | γ = 103.123(2) | |
| V [Å3] | 1293.97(6) | 1382.64(12) | 3817.0(5) | 1106.07(12) |
| Z | 4 | 4 | 8 | 2 |
| 1.547 | 1.515 | 2.113 | 1.961 | |
| μ [mm−1] | 2.355 | 0.250 | 6.657 | 5.754 |
| Max. and min. transm. | 0.7523 and 0.6483 | 0.7461 and 0.7194 | 0.7461 and 0.5932 | 0.7461 and 0.4955 |
| F(000) | 624 | 656 | 2320 | 632 |
| Crystal size [mm] | 0.28 × 0.04 × 0.02 | 0.22 × 0.12 × 0.08 | 0.20 × 0.06 × 0.02 | 0.30 × 0.28 × 0.06 |
| θ range [°] | 3.035–63.142 | 3.131–30.590 | 3.102–30.581 | 3.314–30.535 |
| Limiting indices | −7 ≤ h ≤ 7 | −21 ≤ h ≤ 22 | −27 ≤ h ≤ 27 | −11 ≤ h ≤ 11 |
| −8 ≤ k ≤ 8 | −15 ≤ k ≤ 15 | −20 ≤ k ≤ 21 | −16 ≤ k ≤ 17 | |
| −33 ≤ l ≤ 33 | −12 ≤ l ≤ 12 | −18 ≤ l ≤ 18 | −18 ≤ l ≤ 17 | |
| Reflections collected | 12039 | 21683 | 116299 | 36946 |
| Unique reflections (Rint) | 4055 [0.0508] | 4237 [0.0442] | 5852 [0.1036] | 6724 [0.0198] |
| Completeness to 2θ = 63.142° for | 96.3 % | 99.8 % | 99.8 %. | 99.3 % |
| =25.242° for | ||||
| =25.242° for | ||||
| =25.242°for | ||||
| Data / restraints / parameters | 4055 / 6 / 395 | 4237 / 0 / 207 | 5852 / 0 / 270 | 6724 / 0 / 299 |
| Goodness-of-fit (GOF) on F2 | 1.048 | 0.859 | 1.005 | 1.138 |
| Final | R1=0.0478 | R1=0.0443 | R1=0.0365 | R1=0.0196 |
| wR2=0.0932 | wR2=0.1223 | wR2=0.0531 | wR2=0.0464 | |
| R1=0.0782 | R1=0.0697 | R1=0.0704 | R1=0.0218 | |
| wR2=0.1049 | wR2=0.1417 | wR2=0.0614 | wR2=0.0474 | |
| Largest difference in peak and hole [e Å−3] | 0.315 and −0.411 | 0.416 and −0.417 | 1.279 and −1.402 | 2.564 and −1.526 |
Scheme 1.Synthesis of ligands 3a/3b and their corresponding benzenesulfonamide rhenium tricarbonyl complexes 4a/4b. Conditions and reagents: (i) 1a, NaNO2, NaN3, HCl/THF/DMF (v/v/v: 1:1:1), 0–25 °C, 1 night (93%) or 1b, NaN3, Tf2O, CuSO4.5H2O, K2CO3, CH2Cl2, 0–25 °C, 1 night (85%); (ii) Cu(OAc)2.H2O, sodium ascorbate, CH3CN, 45 °C, 1 night, (3a: 69%, 3b: 61%); (iii) [Re(CO)3Cl], 65 °C, MeOH, 12h, (4a: 67%, 4b: 66%).
Figure 1.Unprecedented cis-configuration of the 2-pyridyl-1,2,3-triazole unit of ligand 3b; a partial view of the crystal packing of 3b with N–H•••N and C–H•••O hydrogen bonds and π–π contacts shown as dashed lines. The purple spheres represent the centroids of the rings involved in π–π interactions.
Figure 2.The molecular structures of rhenium complexes 4a and 4b. Displacement ellipsoids are drawn at 50% probability, solvent molecule (4b) and hydrogen atoms (except H atoms on nitrogen) have been omitted for clarity.
Figure 3.Molecular orbital diagrams of 4a (Left) and 4b (Right).
Inhibition data of human CA I, II and IX isoforms with compounds 3a, 3b, 4a, and 4b in comparison with the standard sulfonamide inhibitor acetazolamide (AAZ) by a stopped-flow CO2 hydrase assay.
| K | Selectivity ratio | ||||
|---|---|---|---|---|---|
| Compound | hCA I | hCA II | hCA IX | I/IX | II/IX |
| 181.3 | 4.1 | 2.8 | 64.75 | 1.46 | |
| 305.2 | 56.1 | 22.5 | 13.56 | 2.49 | |
| 3220.5 | 194.9 | 18.7 | 172.2 | 10.4 | |
| 7146.0 | 836.5 | 27.3 | 261.75 | 30.64 | |
mean from 3 different assays, by a stopped-flow technique (errors in the range of ±5–10% of the reported value).
Italic values are the references values of AAZ (acetalozamide). These are used to compare with our results.